Tech Company M&A Transactions
Amorcyte Acquisition
Headquartered in Allendale, Amorcyte was acquired by NeoStem. The transaction price was $15.3 million.
Transaction Overview
Company Name
Acquired By
Announced On
7/14/2011
Transaction Type
M&A
Amount
$15,260,000
M&A Terms
The definitive merger agreement provides for the issuance of an aggregate of 6,821,283 shares of NeoStem common stock and warrants to purchase an aggregate of 1,881,008 shares of NeoStem common stock. An additional 4,092,768 shares of NeoStem stock will vest upon achievement of specified AMR-001 milestones. Amorcyte shareholders will receive additional consideration in the form of an earn out upon commercialization.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4 Pearl Ct. C
Allendale, NJ 07401
USA
Allendale, NJ 07401
USA
Phone
Website
Email Address
Overview
The company is developing cell therapy products to treat cardiovascular disease, has secured additional funding to complete its first Phase I trial and pursue additional cell therapy opportunities for cardiac and vascular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Andrew Pecora
Chief Financial Officer
Robert Dickey
Chief Medical Officer
Douglas Losordo
Chief Scientific Officer
Robert Preti
VP - Human Resources
David Schloss
VP - Regulatory Affairs
David Altarac
Browse more venture capital transactions:
Prev: 7/14/2011: DVS Sciences venture capital transaction
Next: 7/14/2011: Zettics venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs